title: Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a phase II study.
abstract: OBJECTIVE
  The polychemotherapeutic regimen PEV (cisplatin, epidoxorubicin and vindesine) + lonidamine proved to be valid in terms of activity and efficacy in the treatment of patients with advanced, previously untreated non-small cell lung carcinoma. The goal of the study was to verify whether a different dose of lonidamine, together with an increase in cisplatin and epidoxorubicin compared to the standard regimen, is able to improve the activity and efficacy of PEV without increasing toxicity.
  
  
  METHODS
  Thirty-one patients were treated with cisplatin (80 mg/m2/i.v.), epidoxorubicin (70 mg/m2/i.v.) and vindesine (3 mg/m2/i.v.) every 28 days for 6 courses in combination with lonidamine (600 mg/day on days 1 and 2 of each course followed by 450 mg/day until progression of disease or intolerance). All the patients were monitored for clinical response, median duration of response and survival and for toxicity.
  
  
  RESULTS
  The clinical response in the 29 assessable patients was: 41.4% partial remission, 48.3% stable disease, and 10.3% progression of disease. The median duration of response was 8.5 months (range, 4-26+) and median survival was 12 months (range, 4-26+). Survival was above the median in 15 stage IIIb patients, and 2 patients were long survivors at 26+ months. The toxicity of PEV + lonidamine was mild; there were no toxic deaths nor acute toxicity of grade 4 according to the WHO scoring system.
  
  
  CONCLUSIONS
  Our polychemotherapeutic regimen proved to be valid in terms of activity and efficacy, and a further dose increase in single chemotherapeutic agents as well as lonidamine could therefore be justified.
authors.affiliation: VIIIth Pneumology Division, Carlo Forlanini Hospital, Rome, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Portalone
authors.forename: A
authors.initials: A
authors.lastname: Lombardi
authors.forename: A
authors.initials: A
authors.lastname: Antilli
authors.forename: A R
authors.initials: AR
authors.lastname: Cruciani
authors.forename: V
authors.initials: V
authors.lastname: Magliacani
authors.forename: L
authors.initials: L
authors.lastname: Mugnaini
authors.forename: F
authors.initials: F
authors.lastname: Nunziati
authors.forename: N
authors.initials: N
authors.lastname: Perrone
authors.forename: M
authors.initials: M
authors.lastname: Signora
authors.forename: F
authors.initials: F
authors.lastname: Salvati
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D007191:Indazoles; D015251:Epirubicin; D004317:Doxorubicin; D002945:Cisplatin; D014751:Vindesine; C016371:lonidamine